Comparisone of Iminoral Versus Neoral in Prevention of Acute Rejection in Renal Transplantation
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
Cyclosporine is the key drug in organ transplantation. In Iran the investigators have more
than 2500 new renal transplantation each year and because of this the government pay a huge
amount of money for subsiding the imported cyclosporine in the form of Neoral. Recently an
Iranian drug company introduced this drug in the name of Iminoral which has been approved by
different authorities in Iran and abroad, (including the Ministry of Health in Iran and also
European Directorate for the Quality of Medicines Certification Unit and FDA(Department of
Health and Human Services,Center for Drug Evaluation and Research)). The investigators study
is the first clinical trial to compare the effect of Iminoral versus Neoral in preventing
acute rejection in renal transplantation and also to compare the side effects of these two
drugs.